Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2016 | Editorial Commentary

Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?

Authors: Flavio Nobili, Dario Arnaldi, Silvia Morbelli

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2016

Excerpt

Assessment of the integrity of the nigrostriatal dopaminergic pathway with ¹²³I-ioflupane SPECT has been approved by the Food and Drug Administration and the European Medicines Agency for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). This has fulfilled a previously unmet need, i.e. to support the clinical diagnosis of DLB that is usually difficult because of overlapping symptoms with AD and also with frontotemporal lobe degeneration and vascular cognitive impairment. Indeed, by pooling the results from nine clinicopathological studies including 135 DLB patients and 350 non-DLB patients, the average sensitivity of clinical diagnosis was 49 % (range 0 – 83 %) and the average specificity (proportion of non-DLB patients correctly diagnosed clinically) was 92 % (range 79 – 100 %) [1]. This specificity was considered good but the sensitivity was considered unacceptably low. …

Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467–86.CrossRefPubMed

McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.CrossRefPubMed

McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.CrossRefPubMed

Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176–81.CrossRefPubMedPubMedCentral

McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev. 2015;1, CD010633.PubMed

Colloby SJ, McParland S, O’Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain. 2012;135:2798–808.CrossRefPubMed

Siepel FJ, Rongve A, Buter TC, Beyer MK, Ballard CG, Booij J, et al. (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. BMJ Open. 2013;3:e002642. doi:10.1136/bmjopen-2013-002642.CrossRefPubMedPubMedCentral

van der Zande J, Booij J, Scheltens P, Raijmakers P, Lemstra AW. [123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3312-x

Chung EJ, Kim SJ. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Lewy body-related disorders: a literature review. J Mov Disord. 2015;8:55–66.CrossRefPubMedPubMedCentral

10.

Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology. 2014;83:801–9.CrossRefPubMedPubMedCentral

11.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690–705.CrossRefPubMed

12.

Donaghy PC, McKeith IG. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther. 2014;6:46.CrossRefPubMedPubMedCentral

13.

Fujishiro H, Nakamura S, Sato K, Iseki E. Prodromal dementia with Lewy bodies. Geriatr Gerontol Int. 2015;15:817–26.CrossRefPubMed

14.

Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213–27.CrossRefPubMed

15.

Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. 2013;40:565–73.CrossRefPubMed

Title: Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?
Authors: Flavio Nobili
Dario Arnaldi
Silvia Morbelli
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3323-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2016

18F-DOPA: the versatile radiopharmaceutical

Metabotropic glutamate receptor 5 – a promising target in drug development and neuroimaging

Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET

The Pathophysiologic Basis of Nuclear Medicine, Third Edition, Abdelhamid H. Elgazzar, Ed.

Imaging with 124I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?

Rudy A.J.O. Dierckx, Andreas Otte, Erik F.J. de Vries, Aren van Waarde (eds); guest editor Klaus L. Leenders: PET and SPECT in Neurology